#Ibuprofen API Market

[mitalipingale]

https://justpaste.it/7iraq

The Ibuprofen API Market was US$ 7.4 billion in 2022, and is projected to expand at a CAGR of 3.5% over the forecast period of 2023-2031.

[currentmediasstuff]

Priyanka Chigurupati – Leading Granules India Forward

Priyanka Chigurupati, a dynamic second-generation entrepreneur, is propelling her family’s pharmaceutical business, Granules India, into new heights. Starting her journey with Granules India as a marketing manager for a region-specific division, she quickly rose to oversee a new API facility and establish the US team for Granules Inc.

Early Life and Education

Priyanka’s path to the pharmaceutical industry was not initially clear. After earning a Bachelor of Science in Business Management from Case Western Reserve University in Cleveland, Ohio, she pursued her passion for fashion by obtaining an associate degree in Applied Science (Fashion Marketing) from Parsons, the New School of Design. She launched her fashion label, Chigurupati, designing Western and Indo-Western apparel for young women and retailing through e-commerce platforms, which was a novel approach at the time.

Entering the Family Business

In 2012, Priyanka was invited to join Granules India, the family-owned pharmaceutical company with operations in Hyderabad and the US. Granules India Ltd. is a vertically integrated pharmaceutical company focusing on R&D and multi-product delivery, including the manufacture of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Reflecting on her decision, Priyanka says, “I joined the family business of pharmaceuticals after pondering on what to do post my education in the US.”

Starting as a marketing manager, Priyanka embraced a collaborative approach, valuing collective decision-making over unilateral actions. This philosophy not only facilitated her learning but also instilled the confidence to influence organizational strategy, shifting the company’s focus towards manufacturing excellence.

Career Progression and Achievements

After a brief sabbatical, Priyanka returned to Granules India to manage a newly acquired API facility and subsequently relocated to the US. There, she drove the over-the-counter division as a project manager, later expanding her responsibilities to the prescription side of the business, which posed a new set of challenges due to the company’s limited R&D emphasis at the time. Her efforts culminated in her appointment as Executive Director of Granules Pharmaceuticals Inc. (GPI), where she oversaw the global business front-end, achieving 30+ abbreviated new drug application (ANDA) filings and their commercialization.

Currently, Priyanka leads the entire US generics business, which generates 50% of Granules’ overall revenues. She also manages the company’s portfolio and spearheads investor relations. Under her leadership, Granules has thrived in the competitive US generics market, maintaining a strong presence even as other Indian drug makers retreated from highly commoditized molecules like Paracetamol and Ibuprofen.

Expanding Horizons

Granules is actively expanding its operations, including setting up a new Multi-Unit Pellet System (MUPS) block in Telangana and an API block for medium to high-volume products. Internationally, the company is making inroads into Europe and enhancing its US market share. The company has seen significant growth, with consolidated revenue reaching Rs 2,598.65 crore in FY 19–20 and continued growth during the pandemic, driven by its essential services designation and commitment to uninterrupted medicine supply.

Personal Passions and Inspirations

Beyond her professional achievements, Priyanka is passionate about fitness and fashion, continuing to write and blog on these interests. Inspired by her marathon-running parents, who earned a Guinness World Record in 2010, she brings the same dedication and resilience to her leadership at Granules. Priyanka aims to consolidate and strengthen Granules’ position as a billion-dollar company, empowering her team to share in the organization’s vision with strong conviction and commitment.

Through her strategic vision and innovative leadership, Priyanka Chigurupati is not only honoring her family’s legacy but also ensuring Granules India’s sustained growth and success in the global pharmaceutical industry.

[health-views-updates]

The Evolving Landscape of the Active Pharmaceutical Ingredients Market

In the ever-changing world of pharmaceuticals, one crucial component stands at the forefront of drug development and manufacturing: active pharmaceutical ingredients (API). These are the substances in medications that produce the intended therapeutic effect, making them essential to the pharmaceutical industry. As global health challenges continue to emerge and evolve, the demand for innovative and effective api pharmaceutical products has never been greater.

The active pharmaceutical ingredients market is a complex and dynamic sector, driven by factors such as increasing disease prevalence, aging populations, and advancements in drug discovery technologies. This blog post will explore the current state of the API market, key players, trends, and future prospects.

Understanding APIs and Their Importance

Before delving into the market dynamics, it's essential to understand what is an api in pharmaceutical industry. An API is the biologically active component of a drug that produces the intended effects. For example, in a pain relief medication, the API might be ibuprofen or acetaminophen. The role of api in pharmaceutical manufacturing is crucial, as it determines the efficacy and safety of the final drug product.

Active pharmaceutical ingredient manufacturers play a vital role in the pharmaceutical supply chain. These companies are responsible for producing the APIs that are then used by drug manufacturers to create finished dosage forms. The quality and purity of APIs are of utmost importance, as they directly impact the safety and effectiveness of medications.

Market Overview and Size

The global active pharmaceutical ingredient market has been experiencing steady growth in recent years. According to industry reports, the api market size is expected to reach significant figures in the coming years, driven by factors such as the increasing prevalence of chronic diseases, growing demand for generic medications, and technological advancements in API manufacturing processes.

Key Players and Competition

The API market is highly competitive, with numerous active pharmaceutical ingredient companies vying for market share. Some of the top 10 api pharma companies in world include well-established pharmaceutical giants as well as specialized API manufacturers. These companies invest heavily in research and development to create new and improved APIs, as well as in manufacturing capabilities to ensure consistent quality and supply.

Active pharmaceutical ingredient suppliers play a crucial role in the industry, providing APIs to drug manufacturers worldwide. The competition among suppliers is fierce, with factors such as product quality, regulatory compliance, and pricing all playing significant roles in determining market success.

Trends Shaping the API Market

Several trends are currently shaping the active pharmaceutical ingredients (api) market:

Rise of Generic APIs: The demand for generic api products has been increasing steadily, driven by the need for more affordable medications. Generic api manufacturing has become a significant focus for many API producers, as patents on blockbuster drugs continue to expire.

Increasing Focus on Quality and Regulatory Compliance: With stringent regulations governing the production of APIs, manufacturers are investing heavily in quality control measures and regulatory compliance. This trend is particularly evident in pharma api manufacturing practices.

Shift Towards Specialty and High-Potency APIs: The high potency active pharmaceutical ingredients market is growing rapidly, driven by the development of targeted therapies and personalized medicines.

Outsourcing and Contract Manufacturing: Many pharmaceutical companies are increasingly outsourcing API production to specialized manufacturers, leading to the growth of contract manufacturing organizations (CMOs) in the API sector.

Focus on Sustainability: There is a growing emphasis on developing sustainable manufacturing processes for APIs, including the use of green chemistry principles and reducing environmental impact.

Challenges Facing the API Industry

Despite its growth and importance, the api active pharmaceutical ingredient industry faces several challenges:

Supply Chain Vulnerabilities: The COVID-19 pandemic highlighted vulnerabilities in the active pharmaceutical ingredient supply chain, particularly the heavy reliance on certain countries for API production.

Regulatory Hurdles: Stringent regulations and the need for compliance with various international standards can be challenging for API manufacturers, particularly smaller companies.

Price Pressures: Increasing competition, especially in the generic API sector, has led to significant price pressures on manufacturers.

Technological Challenges: Developing and manufacturing complex APIs, particularly for biologics and other advanced therapies, requires significant technological expertise and investment.

The Role of APIs in Drug Development

Understanding api in pharmaceutical industry is crucial for grasping the drug development process. APIs are at the heart of new drug discoveries and play a vital role in determining the efficacy and safety profiles of medications. The development of novel APIs is a complex and time-consuming process, often taking years of research and testing before a new active pharmaceutical ingredient api is approved for use in medications.

Api pharma companies invest heavily in research and development to discover new APIs that can address unmet medical needs or improve upon existing treatments. This ongoing innovation is crucial for advancing medical treatments and improving patient outcomes.

The Importance of API Quality and Safety

Ensuring the quality and safety of APIs is paramount in the pharmaceutical industry. Active pharmaceutical ingredients manufacturers must adhere to strict quality control measures and follow Good Manufacturing Practices (GMP) to ensure that their products meet the highest standards of purity and efficacy.

The active pharmaceutical ingredient list of approved substances is carefully regulated by health authorities worldwide. Each pharmaceutical ingredient must undergo rigorous testing and evaluation before it can be used in medications.

Global Market Dynamics

The global nature of the API market presents both opportunities and challenges. While many active pharmaceutical ingredient manufacturers in usa play a significant role in the industry, a large portion of API production occurs in other countries, particularly India and China. This global distribution of manufacturing has implications for supply chain resilience, quality control, and regulatory oversight.

Us active pharmaceutical ingredient manufacturers have been working to increase domestic production capabilities, particularly in light of recent supply chain disruptions. This shift towards more localized production could have significant impacts on the global API market in the coming years.

The Future of the API Market

As we look to the future, several factors are likely to shape the active pharmaceuticals ingredients market:

Continued Innovation: The development of new and improved APIs will remain crucial for addressing emerging health challenges and improving existing treatments.

Emphasis on Specialty and Biologic APIs: The trend towards personalized medicine and biologic drugs is likely to drive growth in specialty and high-potency APIs.

Sustainability: Environmental concerns and regulatory pressures will likely lead to increased focus on sustainable API production methods.

Supply Chain Resilience: Efforts to diversify and strengthen the global API supply chain are likely to continue, potentially reshaping the geographic distribution of manufacturing.

Technological Advancements: Innovations in areas such as continuous manufacturing and AI-driven drug discovery could significantly impact API production and development.

Conclusion

The active pharmaceutical ingredients (api) market plays a crucial role in the global pharmaceutical industry. As the demand for both innovative and generic medications continues to grow, the importance of APIs in ensuring public health cannot be overstated.

Understanding what is active pharma ingredients and their role in drug development and manufacturing is essential for anyone involved in or interested in the pharmaceutical sector. From the complex processes of api pharmaceutical manufacturing to the intricacies of the global supply chain, APIs are at the heart of modern medicine.

As the market continues to evolve, collaboration between active pharma ingredients manufacturers, regulatory bodies, and pharmaceutical companies will be crucial in addressing challenges and capitalizing on opportunities. The future of the API market looks promising, with continued innovation and growth expected in the coming years.

Whether you're a professional in the pharmaceutical industry, a healthcare provider, or simply someone interested in understanding what is active pharmaceutical ingredient, staying informed about the API market is crucial. As this dynamic sector continues to evolve, it will undoubtedly play a pivotal role in shaping the future of global healthcare.

[nidarsanafwr]

https://app.socie.com.br/read-blog/96508_global-ibuprofen-api-market-size-overview-key-players-and-forecast-2031.html

Global Ibuprofen API Market Size, Overview, Key Players and Forecast 2031

[sabalevaishali]

Ibuprofen API Market Overview:

There has been significant progress in the pharmaceutical industry for developing novel drugs with efficiency. These innovations have eased the burden off healthcare professionals and patients in streamlining the drug manufacturing and decreasing development cost. Furthermore, the rising prevalence of arthritis around the world has boosted the ibuprofen API market growth. Ibuprofen is administered to a patient with a high dosage only if the patient is diagnosed with inflammatory arthritis or rheumatoid arthritis. With doses of over 1100 mg per day, the effect of ibuprofen is like the effect of aspirin in treating rheumatoid arthritis. Contract manufacturing organizations are realigning their strategies with the changing pharmaceutical industry. Many key players are dependant on CMOs in supply chain management of these companies and these are now normal proceedings.

[vijayanger12]

The global Ibuprofen API market size is estimated to be worth US$ 681 million in 2022 and is forecast to a readjusted size of US$ 928.4 million by 2030 with a CAGR of 5.3% during the review period.

[ziyadnazem]

America’s dependence on China for pharmaceuticals: 97% of all antibiotics in the United States came from China

In the midst of an ongoing quarantine across China due to the 2019 Coronavirus outbreak, it is rather troubling to be reminded about the dependence of America on China for products, particularly essential medicine.

Back in July of 2019, the U.S.-China Economic and Security Review Commission held a hearing on the growing reliance of China's biotech and pharmaceutical products in America. The topic reminded me of a spirited discussion described in Bob Woodward’s book, Fear: Trump in the White House. In the discussion, Gary Cohn, then chief economic advisor to President Trump, argued against a trade war with China by invoking a Department of Commerce study that found that 97% of all antibiotics in the United States came from China. “If you’re the Chinese and you want to really just destroy us, just stop sending us antibiotics,” he said.

Cohn’s words highlight a security concern associated with pharmaceuticals from China. As Rosemary Gibson noted in her testimony, centralization of the global supply chain of medicines in a single country makes it vulnerable to interruption, “whether by mistake or design.” If we are dependent on China for thousands of ingredients and raw materials to make our medicine, China could use this dependence as a weapon against us. While the Department of Defense only purchases a small number of finished pharmaceuticals from China, about 80 percent of the active pharmaceutical ingredients (APIs) used to make drugs in the United States are said to come from China and other countries like India. For example, the chemical starting material used to make doxycycline, the recommended treatment for anthrax exposure, comes from China. When an influential Chinese economist earlier this year suggested that Beijing curb its exports of raw materials for vitamins and antibiotics as a countermeasure in the trade war with the United States, the worries surrounding our API dependence to China seemed to be vindicated. Concern about a disruption in the supply chain could explain why the tariffs on Chinese products proposed by the United States Trade Representative in May 2019, worth approximately $300 billion, excludes “pharmaceuticals, certain pharmaceutical inputs, and select medical goods.”

While the potential exposure to raw material supply disruptions drives part of our fear, concern about the safety and efficacy of Chinese-made pharmaceuticals is another component. In the summer of 2018, one of China’s largest domestic vaccine makers sold at least 250,000 substandard doses of vaccine for diphtheria, tetanus, and whooping cough. It was the latest in a slew of scandals caused by poor quality drug products made in China over the last decade. In 2008, the contamination of a raw ingredient imported from China and used to make heparin, a blood-thinning drug, was associated with at least eighty-one deaths in the United States. According to an investigative journalist, fraud and manipulation of quality data are still endemic in Chinese pharmaceutical firms.

In order to address the growing security and safety concerns about Chinese-made pharmaceuticals, some suggest that the United States switch to India as an alternative API supplier. However, doing so would be no different from rearranging the deck chairs on the Titanic. It is true that many Indian pharmaceutical firms are leading API manufacturers but India depends on China for sourcing nearly three-quarters of APIs in generic drug formulations. The disruption in the supply chain notwithstanding, switching to India for the supply of APIs would only make the drugs sold in the United States more expensive: APIs and chemical intermediates from China are 35 to 40 percent cheaper than Indian ones. Moreover, India has its own drug safety problems as well. In 2013, a generic drug maker in India pled guilty to drug safety charges, which included shipping batches of adulterated drugs, having incomplete testing records, and inadequate programs to assess drug quality. According to a former executive of the company, this was only a fraction of the safety issues the Food and Drug Administration (FDA) could identify in overseas plants.

Moreover, we could have overestimated our dependence on Chinese-made pharmaceutical products. As of 2018, China claimed 13.4% of all import lines; defined as distinct regulated products within a shipment through customs–among countries that export drugs and biologics to the United States. Of these import lines for drugs and biologics, about 83% were finished drugs, and only 7.5% were APIs. We certainly underestimate the share of APIs from China given that Chinese-made APIs can come to the United States as part of the finished drug products from other countries like India. However, the lack of a reliable API registry makes it difficult to estimate the true market share of Chinese-made APIs.

In addition, when highlighting our dependence on Chinese-made pharmaceuticals, we could overlook the other side of the coin: China needs finished drugs made in the United States. China is facing a crisis of non-communicable diseases, including cancer, cardiovascular diseases, and diabetes. It is estimated that between 2002 and 2016, new cancer cases in China increased by more than 55%, from 2.19 million to 3.8 million. A majority of Chinese cancer patients, however, lack access to the most effective drugs. Partly because of this, cancer survival rate in China is less than half of the United States. Under the performance-based legitimacy in contemporary China, the government must justify its rule by continuously delivering public goods and services, like better healthcare, to meet people’s wants. In an increasingly state-dominated political system, the link between performance and legitimacy becomes so tight that failure to deliver such goods could endanger the system itself. In the meantime, with the rapid improvement of material living standards, Chinese people are increasingly valuing things beyond basic earnings, such as good health. As President Xi Jinping stated in the 19th Party Congress, the “principal contradiction” in the society is “the contradiction between unbalanced and inadequate development and the people’s ever-growing needs for a better life.” In fact, in 2018, the government cut the import value-added tax on cancer drugs from 17 percent to 3 percent and reduced import tariffs on all common drugs and cancer drugs to zero. Essentially, regime legitimacy requires the state to deliver the most effective drugs, which are often patented and provided exclusively by multinational pharmaceutical companies. In May 2019, China unveiled a list of imported U.S. medical products to impose punitive tariffs upon. The list includes commonly used drugs such as insulin, ibuprofen, as well as medical devices such as ultrasonic diagnostic apparatuses and endoscopes, which Chinese firms can manufacture themselves. Nevertheless, the list did not include anti-cancer drugs and other patented ones.

The same legitimacy concern also led the Chinese government to introduce incentives to improve the quality of its pharmaceutical products. In 2016, China’s FDA introduced the Generic Consistency Evaluation (GCE), which required generic drugs approved for production prior to 2008 to pass the GCE in order to gain “equivalence” to branded drugs in terms of safety and efficacy. Failure to pass the GCE in a timely manner will lead to the revocation of registration licenses or ineligibility for government tenders. Since generic drugs approved before 2008 are prone to low-quality problems, a significant number of drugs that have failed to pass GCE are expected to exit the public market. The measure will help weed out over half of the nation’s 2,900 or so small, and often low-quality, domestic drug makers. Since early this year, nearly 20 pharmaceutical firms have either exited the industry or been reorganized.

So what does all this mean for a response from the United States? Before making any major decisions on this issue, it is important to collect as much information as possible for a full assessment of the risks we face. We should also nurture the development of alternative sources and capabilities to make critically essential drugs in the United States.

[snehasingh9012-blog]

Analyzing the Impact of COVID-19: Downtrend Prevails in Ibuprofen API Market; Supply Chains May Continue to Suffer Through 2020 - Future Market Insights

DUBAI, UAE / ACCESSWIRE / May 5, 2020 / Active pharmaceutical ingredient (API) industry is witnessing a sharp decline in supply and demand during the COVID-19 outbreak. Ibuprofen API will witness a downfall in demand, owing to halted productions by major manufacturers, as suggested by a new Future Market Insights (FMI) report. Continuous demand for low-cost non-steroidal anti-inflammatory drugs (NSAIDs), and scale of manufacturing facilities remain the key drivers for global Ibuprofen market that has been projected to witness around 1.3X expansion in revenues during 2020-2029.

Emergence of cost-effective drug manufacturers in Asia, coupled with increasing API drug shortages, are further driving ibuprofen API market growth. Moreover, with China being the global manufacturing hub, is severely affected by the pandemic induced travel restrictions and lockdowns, eventually resulting in supply chain disruptions. The effects of COVID-19 are collectively resulting in a decline in sales. The downtrend is expected to prevail till the pandemic subsides.

Download a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-11260

Segmental Highlights:

Contract Manufacturing Organizations (CMOs) will remain the primary end-use segment, owing to high reliance from prominent pharmaceutical companies for manufacturing APIs as well as final formulations. Furthermore, the integration of CMOs into the supply chain of pharmaceutical companies is gradually gaining traction, propelling the demand.

North America is currently the leading regional market for Ibuprofen API. The dominance is attributed to the strong presence of leading manufacturers, coupled with high adoption of non-steroidal anti-inflammatory drugs (NSAID). However, the region will end up shrinking its global market share owing to Asia's proliferation.

Asian market is forecasted to grow at a promising rate and bestow lucrative opportunities for players in the ibuprofen API market. The growth is primarily attributed to the availability of cheap labor adequate raw materials. Moreover, with conducive regulatory environments being set up across manufacturing facilities, coupled with reduced taxation policies are fueling growth. China and India being leading regions, contribute to 80% of total anti-inflammatory APIs manufactured. This facet is further spurring market players to leverage the demand in the region. However, the pandemic is likely to hinder the swift growth of the market.

For information on the research approach used in the report, request methodology@ https://www.futuremarketinsights.com/askus/rep-gb-11260

Report coverage:

End-use Industries: Contract Manufacturing Organizations and Pharmaceutical Companies

Regions: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, and MEA

Explore FMI's Lucid Coverage of Healthcare Landscape

Veterinary Vaccines Market- The veterinary vaccines market study analyses the key trends, innovations, regulatory policies, and key strategies adopted by leading players in this evolving landscape.

Peptide Therapeutics Market- The study analyses the peptide therapeutics market and offers growth opportunities in USD million across 30+ countries in six regions.

Digital Pathology Market- With strong growth through 2029, the digital pathology market is witnessing substantial growth in a market.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Mr. Abhishek Budholiya Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates MARKET ACCESS DMCC Initiative For Sales Enquiries: sales@futuremarketinsights.com For Media Enquiries: press@futuremarketinsights.com Report: https://www.futuremarketinsights.com/reports/ibuprofen-api-market Press Release Source: https://www.futuremarketinsights.com/press-release/ibuprofen-api-market

SOURCE: Future Market Insights

[mitalipingale]

The Ibuprofen API Market was US$ 7.4 billion in 2022, and is projected to expand at a CAGR of 3.5% over the forecast period of 2023-2031.

[swarajya7793]

COVID-19 Impact on API Intermediate Market in Pharmaceuticals Industry | Data Bridge Market Research

COVID-19 Impact on API Intermediate Market in Pharmaceuticals Industry

Coronavirus (COVID-19) is a novel disease which was first originated in China, Wuhan and then spread worldwide due to which World Health Organization has declared it as a global pandemic. The novel strain of coronavirus belongs to the same virus family that causes the acute respiratory syndrome (SARS) and middle-east respiratory syndrome.

Due to rapid growth of Coronavirus, lockdown and quarantine was the government initiatives in order to control the coronavirus spread. Therefore, these initiatives have created an unpredictable effect on both human daily lives and on global economy along with that the global pandemic of COVID-19 is affecting the health and personal decision-making of people.

APIs are the effective ingredient present in the medicine, and even small amount of active ingredients known to produce effective result. The APIs are manufactured using the raw materials which are known as intermediates. The intermediates are the key products for carrying out the process of formulating the active pharmaceutical ingredients. API and the intermediate market is such a huge market and has a great application in the medical field there is a huge demand of close monitoring of manufacturing process. But due to continuous pandemic of COVID 19 and long term shut down has put an adverse effect on overall drug manufacturing companies. The governments of several countries have reported that there is huge scarcity of APIs and intermediates amid the COVID 19 pandemic. The reason behind that is the barrier across the countries border that has an ultimatum effect over the import and export facilities of medicinal product among others.

The effect of COVID-19 is different for every industries and their products. Mainly COVID19 affect the economy by three different ways:

·         By affecting the demand of product /services,

·         Affecting the price,

·         Affecting the supply chain.

Demand of various API intermediates product and raw material increased in the pandemic situation of COVID19 due to increase in more respiratory disorder and people investing more in healthcare. 

BASF SE, Winthrop (A Sanofi Company), A.R.Life Sciences, Aceto are leading pharmaceutical companies for manufacturing API intermediates. Their sales affected due to the COVID situation because the supply of the intermediates were banned during the lockdown.

IMPACT ON PRICE

The COVID-19 outbreak led to a number of countries putting their citizens on various forms of lockdowns, although the terms differ from country to country. India and China are among the countries that have imposed highly restrictive mass quarantines that have impacted several markets and their economies. India and China is considered as one of the countries dealing with highest share in the field of APIs and their intermediates, as there were lockdown policies and all borders were closed so there has been a huge impact on the pricing as the active pharmaceutical ingredients and their intermediates are not available adequately.

Due to some factors such as disruption in supply chain, the cost of the APIs and their intermediates have increased up to 40-50% in India especially for the medicines such as paracetamol, penicillin and anti-asthma drugs. As there was risk in supply chain during the COVID-19 and there was a delay in the supply chain. The air shipments were decreased and the price of the shipment was increased by three times which will increase the price of the APIs and their intermediates as the shipment charges were increased.

There is increase in the demand for the API intermediates which are used for manufacturing of finished drugs. However, fear of COVID 19 infection is a major factor that effect the demand of products.

The price of many products increased due to great effect of COVID 19 on the supply chain of products and other factor responsible for the increase in price due to the demand of product.

For instance,

·         In January 2018-19, Indian pharmaceutical companies imported bulk drugs and intermediates worth USD 2.4 billion from China, which was about 68% of total imports of the raw material. While most large companies usually keep an inventory for about two to three months due to fluctuating supply and prices of bulk drugs, if the crisis continues, they will have to consider other options, including buying them from other areas at a higher price

·         High demand for the supply of 1- (4-isobutylphenyl) ethanol (4-IBPE) API intermediate of Ibuprofen globally has resulted in a 30 per cent spike in prices. The API or bulk drug (raw material) of Ibuprofen has seen supply shortages in the 3 quarters in 2020, due to production disruption in India in January and subsequently in China which are the major supplier.

Therefore, as the production of the APIs have been slower down by the manufacturing companies which has resulted in lower availability and increased the cost of the materials that is required in the production of finished products.

IMPACT ON DEMAND

As during the pandemic, the supply of active ingredients for major chronic diseases has been shut down, increasing the demand for the product more.

Due to the spread of COVID-19, there is a lockdown in the world which leads to the closure of manufacturing plants and distribution channels, plus worker being held up to their homes slow down the production and supply of API intermediates which badly affected the global economy and also affect the demand of many products which indirectly increases the demand and need for the pharmaceutical product by the people.

During COVID-19, there was a slight change in the demand for APIs and intermediates as the manufacturing companies were involved in finding the novel treatment for the COVID-19 patients. There was an increase in demand for antiviral APIs and intermediates. The other chronic diseases were untreated as the demand was decreased from the consumer side due to fear in the patient population of the exposure of the virus. Read more…

[rajesh1112]

The global market value was $573 million in 2019. It is expected to grow at a steady rate of 2–3 percent, due to continuous demand for low-cost non-steroidal anti-inflammatory drugs (NSAID) and the scale and age of manufacturing facilities.

The pharmaceutical industry is the end-use industry for Ibuprofen. The increasing API drug shortages, gathering task force to overcome shortages, the emergence of cost-effective drug manufacturers in different countries, and supply of API drugs in the developed nations are driving the API growth.

[nidarsanafwr]

Global Ibuprofen API Market Size, Overview, Key Players and Forecast 2031

[riyaus]

Vital Signs Monitoring Devices Market Size, Share, Growth Factor 2021 Ibuprofen Market 2021 Ibuprofen is an API used for the manufacturing of a nonsteroidal anti-inflammatory medication for treating pain, fever, and inflammation. It is a derivative of propionic acid used for relieving pain, helping with fever, and reducing inflammation. Other advantages associated with Ibuprofen, include rapid…

[chris-harris-blog]

Ibuprofen Api Market Size and Forecast from 2020-2027 | by Basf Se, Biocause Inc, Iol Chemicals And Pharmaceuticals Limited

Ibuprofen Api Market Size and Forecast from 2020-2027 | by Basf Se, Biocause Inc, Iol Chemicals And Pharmaceuticals Limited

The Global Ibuprofen Api Market is anticipated to rise at a considerable rate during the forecast period. In the recent years, the market was growing at a steady rate and with the rising adoption of strategies by key players; the Ibuprofen Api market is expected to rise over the Forecast Period of 2020-2027. Book NOW! PDF of Sample Research Report, Today Report Scope: Top Manufacturers…